TNFRSF1B and ovarian carcinoma: Torrey et al. [33] and Vanamee and Faustman [34] found that targeting TNFR2 with antagonistic antibodies significantly inhibited the proliferation of ovarian cancer cells, and the follow-up study confirmed the therapeutic effects of TNFR2 antibodies on other tumors [35].